BLCOBLCOHealthcare · Medical Instruments & Supplies

BLCO Stock Forecast: Bausch + Lomb Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$19
−6.33% on the day

The 14 Wall Street analysts covering Bausch + Lomb Corp. hold a median 12-month price target of $22 — +13.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 99 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$6.9B
Ticker Nerd rank
99/ 100
Median analyst target
$22
Analysts covering
14
Revenue$1.4B+9.1% y/y
Operating income$108.0M
Net income−$10.0M
Free cash flow$82.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.1%
1M
+14.5%
YTD
+13.5%
1Y
+33.1%
From 52W high
−9.3%
From 52W low
+33.1%
$15
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Bausch + Lomb Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
99/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Revisions
93
Volatility
93
Quality
91
Growth
89
Momentum
87
Accruals
68
Issuance
43

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (43): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BLCO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLCO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25Jan 26Apr 26Jul 26Oct 26BLCOHigh $27Median $22Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
5
Buy
8
Hold
1
Sell
$18
Low
$22
Median
$27
High

The green dot is the last close — the median target sits +13.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Nov 2026BarclaysMaintainsOverweight$24 → $27
2 Nov 2026HC Wainwright & Co.DowngradeNeutral$21 → $22
29 Oct 2026CitigroupMaintainsBuy$21 → $23
29 Oct 2026JP MorganMaintainsNeutral$16 → $22
29 Oct 2026RBC CapitalMaintainsOutperform$21 → $23
29 Oct 2026Wells FargoMaintainsEqual-Weight$18 → $19
7 Oct 2026BarclaysInitiatesOverweight$24
15 Sept 2026NeedhamReiteratesHold—
9 Sept 2026Leerink PartnersInitiatesOutperform$24
28 Aug 2026HC Wainwright & Co.ReiteratesBuy$21
3 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $21
30 July 2026UBSMaintainsBuy$21 → $23
28 July 2026UBSInitiatesBuy$21
8 July 2026CitigroupMaintainsBuy—
6 July 2026Evercore ISI GroupMaintainsIn-Line$16 → $17
30 Apr 2026CitigroupMaintainsBuy—
30 Apr 2026Evercore ISI GroupMaintainsIn-Line—
6 Apr 2026Evercore ISI GroupMaintainsIn-Line—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
19 Feb 2026BarclaysMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BLCO.

Market Radar

This page is one stock. Monday covers all of them.

BLCO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BLCO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Bausch + Lomb Corp. returned +33.1% against +6.9% for the S&P 500, dividends included.

BLCO vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140150Jan 26Apr 26Jul 26Oct 26BLCOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BLCO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+17.5%
Analysts raising
13
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.3×

Cheaper than 60% of US stocks

Price / book
1.1×

Cheaper than 68% of US stocks

EV / EBITDA
12.7×

Cheaper than 43% of US stocks

Growth & margins
Revenue growth (YoY)
7.3%

Higher than 47% of US stocks

Earnings growth (YoY)
—
Gross margin
62.2%

Higher than 75% of US stocks

Operating margin
9.4%

Higher than 62% of US stocks

Net margin
−2.0%

Higher than 28% of US stocks

Returns & dividend
Return on equity
−1.6%

Higher than 43% of US stocks

Return on assets
2.3%

Higher than 59% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bausch + Lomb Corp. has a market value of $6.9B and an enterprise value of $11.6B.

  • Revenue in the twelve months to 30 June 2026: $5.3B. The latest quarter grew 9.1% year on year.

  • Net income over the same four quarters: −$163.0M, a −3.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.48.

  • Free cash flow in the twelve months to 30 June 2026: $137.0M.

  • Shares outstanding: 357.1M.

  • forward P/E: 16.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bausch + Lomb Corp. employs 13,000 people — $410K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

BLCO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BLCOBausch + Lomb Corp.$6.9B99
TFXTeleflex, Inc.$6.4B93
ATRAptarGroup, Inc.$9.2B62
MMSIMerit Medical Systems, Inc.$5.0B86
AVTRAvantor, Inc.$10.1B83
RGENRepligen Corp.$10.4B87
MMEDMiniMed Group, Inc.$4.5B1

Take a look at BLCO’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Bausch + Lomb Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BLCO

What is the BLCO stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Bausch + Lomb Corp. have a median 12-month price target of $22, with estimates ranging from $18 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLCO stock a buy right now?

Of the 14 analysts covering Bausch + Lomb Corp., 5 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bausch + Lomb Corp. 99 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLCO?

As at 21 Nov 2026, Bausch + Lomb Corp. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will BLCO stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +13.5% from the last close, and Ticker Nerd's factor model ranks Bausch + Lomb Corp. 99 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLCO stock forecast for 2030?

No analyst covering Bausch + Lomb Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLCO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $27 over the next 12 months.

How has BLCO stock performed over the past year?

Bausch + Lomb Corp. returned +33.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bausch + Lomb Corp. do?

Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision care, surgical care, and ophthalmic pharmaceuticals. Bausch + Lomb offers contact lenses, lens care solutions, eye drops, vitamins and supplements, and prescription therapies for a range of eye conditions.

Company

About Bausch + Lomb Corp.

Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision care, surgical care, and ophthalmic pharmaceuticals. Bausch + Lomb offers contact lenses, lens care solutions, eye drops, vitamins and supplements, and prescription therapies for a range of eye conditions. Its surgical portfolio includes intraocular lenses, ophthalmic surgical devices, and instruments used in cataract and other eye procedures. The company serves consumers, eye care professionals, and healthcare providers across international markets, supporting routine vision maintenance as well as more specialized clinical treatment. Headquartered in Vaughan, Ontario, Canada, Bausch + Lomb focuses exclusively on eye health and remains a recognized name in the medical devices and ophthalmic goods industry.

CEO Mr. Thomas J. Appio · 13,000 employees · Canada · https://www.bausch.com